Mark Schoenberg, serving as the Chief Medical Officer for UroGen Pharma Ltd. (NASDAQ: URGN), completed a divestment of 10,000 ordinary shares on June 22, 2026. The total proceeds from this transaction amounted to $350,100. Each share was transacted at a weighted average price of $35.01, with the specific execution falling within a narrow price band between $35.00 and $35.08. This sale was facilitated through a pre-arranged 10b5-1 trading plan, which was initially adopted on August 15, 2025, ensuring compliance with regulatory frameworks for insider transactions.
The timing of this insider sale is notable as UroGen's equity trades in close proximity to its 52-week high of $35.58. This price level underscores a remarkable 155% return over the past year, indicating significant market appreciation for the company's prospects. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value estimate, with 15 additional ProTips available to subscribers.
Following the recent transaction, Mr. Schoenberg's direct ownership position stands at 129,763 ordinary shares of UroGen Pharma. This holding reflects his continued equity stake in the company despite the partial liquidation.
UroGen Pharma has recently been the center of attention due to several pivotal developments. The company announced a settlement and license agreement with Teva Pharmaceuticals, effectively resolving patent litigation that arose from Teva's attempt to market a generic version of UroGen's Jelmyto. This settlement provides UroGen with approximately four years of additional market protection, extending close to the January 2031 patent expiry. This extension is critical for maintaining revenue streams from its key product.
In response to the settlement, H.C. Wainwright reaffirmed a Buy rating for UroGen Pharma, while Oppenheimer reiterated an Outperform rating. Both analysts highlighted the positive impact of the settlement on the company's long-term prospects. Furthermore, UroGen reported promising data from its clinical trials, specifically regarding its investigational drug UGN-103. In the Phase 3 UTOPIA trial for patients with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, UGN-103 demonstrated a 94.5% durability of response at six months. These results align with the 91.9% six-month durability of response observed with ZUSDURI, UroGen's FDA-approved treatment for the same condition.
Additionally, UroGen reported a 36-month duration of response of 64.5% in patients who achieved a complete response at three months in the Phase 3 ENVISION trial. Based on this durability data, H.C. Wainwright reiterated a Buy rating, maintaining a $45 price target for the stock. This data suggests potential for UGN-103 to compete effectively in the urology sector, impacting the broader pharmaceutical industry's competitive landscape for bladder cancer treatments.